Cargando…

Long-term analysis of multimodality treatment outcomes and prognosis of esthesioneuroblastomas: a single center results of 138 patients

BACKGROUND: The aim of this study is to evaluate the efficacy of different treatment strategies and the potential prognostic factors of esthesioneuroblastoma (ENB). MATERIALS AND METHODS: Between April 1984 and December 2018, 138 patients with non-metastatic ENB were retrospectively analyzed. The tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Meng, Wang, Kai, Qu, Yuan, Zhang, Jianghu, Zhang, Shiping, Chen, Xuesong, Wang, Jingbo, Wu, Runye, Zhang, Ye, Yi, Junlin, Xiao, Jianping, Xu, Guozhen, Huang, Xiaodong, Luo, Jingwei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7501706/
https://www.ncbi.nlm.nih.gov/pubmed/32948223
http://dx.doi.org/10.1186/s13014-020-01667-4
_version_ 1783584083307134976
author Sun, Meng
Wang, Kai
Qu, Yuan
Zhang, Jianghu
Zhang, Shiping
Chen, Xuesong
Wang, Jingbo
Wu, Runye
Zhang, Ye
Yi, Junlin
Xiao, Jianping
Xu, Guozhen
Huang, Xiaodong
Luo, Jingwei
author_facet Sun, Meng
Wang, Kai
Qu, Yuan
Zhang, Jianghu
Zhang, Shiping
Chen, Xuesong
Wang, Jingbo
Wu, Runye
Zhang, Ye
Yi, Junlin
Xiao, Jianping
Xu, Guozhen
Huang, Xiaodong
Luo, Jingwei
author_sort Sun, Meng
collection PubMed
description BACKGROUND: The aim of this study is to evaluate the efficacy of different treatment strategies and the potential prognostic factors of esthesioneuroblastoma (ENB). MATERIALS AND METHODS: Between April 1984 and December 2018, 138 patients with non-metastatic ENB were retrospectively analyzed. The treatment modalities mainly included surgery alone (n = 7), radiotherapy alone (n = 33), concurrent chemoradiotherapy (n = 17), surgery combined with current chemoradiotherapy (n = 32), and surgery plus radiotherapy (n = 49). RESULTS: The median follow-up time for the entire cohort was 61 months (range, 4–231 months). The 5-year overall survival (OS), locoregional failure-free survival (LRFFS), and distant metastasis-free survival (DMFS) rate were 69.6, 78.0 and 73.9%, respectively. Surgery combined with radiotherapy elicited superior survival results, and the combination of surgery and current chemoradiotherapy achieved the best prognoses for all patients, patients with advanced Kadish disease, patients receiving intensity modulated radiation therapy and those with positive surgical margin. Univariate analysis identified orbital invasion and treatment modalities were predictors for OS, LRFFS and DMFS. Lymph node metastasis was associated with OS and DMFS, but not LRFFS. Intracranial invasion, advanced Kadish stage and not receiving concurrent chemotherapy were also predictive of lower OS. Multivariate analyses indicated that lymph node metastasis was an independent prognostic factor affecting DMFS, whereas treatment modalities was independent prognostic factors for OS and LRFFS. CONCLUSION: Orbital invasion, intracranial invasion, lymph node metastasis and advanced Kadish disease at initial diagnosis were significantly associated with inferior prognosis. Regarding the treatment modality, the optimal strategy remined surgery with radiotherapy-based multimodality treatment. The concurrent chemoradiotherapy may play a more beneficial role.
format Online
Article
Text
id pubmed-7501706
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-75017062020-09-22 Long-term analysis of multimodality treatment outcomes and prognosis of esthesioneuroblastomas: a single center results of 138 patients Sun, Meng Wang, Kai Qu, Yuan Zhang, Jianghu Zhang, Shiping Chen, Xuesong Wang, Jingbo Wu, Runye Zhang, Ye Yi, Junlin Xiao, Jianping Xu, Guozhen Huang, Xiaodong Luo, Jingwei Radiat Oncol Research BACKGROUND: The aim of this study is to evaluate the efficacy of different treatment strategies and the potential prognostic factors of esthesioneuroblastoma (ENB). MATERIALS AND METHODS: Between April 1984 and December 2018, 138 patients with non-metastatic ENB were retrospectively analyzed. The treatment modalities mainly included surgery alone (n = 7), radiotherapy alone (n = 33), concurrent chemoradiotherapy (n = 17), surgery combined with current chemoradiotherapy (n = 32), and surgery plus radiotherapy (n = 49). RESULTS: The median follow-up time for the entire cohort was 61 months (range, 4–231 months). The 5-year overall survival (OS), locoregional failure-free survival (LRFFS), and distant metastasis-free survival (DMFS) rate were 69.6, 78.0 and 73.9%, respectively. Surgery combined with radiotherapy elicited superior survival results, and the combination of surgery and current chemoradiotherapy achieved the best prognoses for all patients, patients with advanced Kadish disease, patients receiving intensity modulated radiation therapy and those with positive surgical margin. Univariate analysis identified orbital invasion and treatment modalities were predictors for OS, LRFFS and DMFS. Lymph node metastasis was associated with OS and DMFS, but not LRFFS. Intracranial invasion, advanced Kadish stage and not receiving concurrent chemotherapy were also predictive of lower OS. Multivariate analyses indicated that lymph node metastasis was an independent prognostic factor affecting DMFS, whereas treatment modalities was independent prognostic factors for OS and LRFFS. CONCLUSION: Orbital invasion, intracranial invasion, lymph node metastasis and advanced Kadish disease at initial diagnosis were significantly associated with inferior prognosis. Regarding the treatment modality, the optimal strategy remined surgery with radiotherapy-based multimodality treatment. The concurrent chemoradiotherapy may play a more beneficial role. BioMed Central 2020-09-18 /pmc/articles/PMC7501706/ /pubmed/32948223 http://dx.doi.org/10.1186/s13014-020-01667-4 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Sun, Meng
Wang, Kai
Qu, Yuan
Zhang, Jianghu
Zhang, Shiping
Chen, Xuesong
Wang, Jingbo
Wu, Runye
Zhang, Ye
Yi, Junlin
Xiao, Jianping
Xu, Guozhen
Huang, Xiaodong
Luo, Jingwei
Long-term analysis of multimodality treatment outcomes and prognosis of esthesioneuroblastomas: a single center results of 138 patients
title Long-term analysis of multimodality treatment outcomes and prognosis of esthesioneuroblastomas: a single center results of 138 patients
title_full Long-term analysis of multimodality treatment outcomes and prognosis of esthesioneuroblastomas: a single center results of 138 patients
title_fullStr Long-term analysis of multimodality treatment outcomes and prognosis of esthesioneuroblastomas: a single center results of 138 patients
title_full_unstemmed Long-term analysis of multimodality treatment outcomes and prognosis of esthesioneuroblastomas: a single center results of 138 patients
title_short Long-term analysis of multimodality treatment outcomes and prognosis of esthesioneuroblastomas: a single center results of 138 patients
title_sort long-term analysis of multimodality treatment outcomes and prognosis of esthesioneuroblastomas: a single center results of 138 patients
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7501706/
https://www.ncbi.nlm.nih.gov/pubmed/32948223
http://dx.doi.org/10.1186/s13014-020-01667-4
work_keys_str_mv AT sunmeng longtermanalysisofmultimodalitytreatmentoutcomesandprognosisofesthesioneuroblastomasasinglecenterresultsof138patients
AT wangkai longtermanalysisofmultimodalitytreatmentoutcomesandprognosisofesthesioneuroblastomasasinglecenterresultsof138patients
AT quyuan longtermanalysisofmultimodalitytreatmentoutcomesandprognosisofesthesioneuroblastomasasinglecenterresultsof138patients
AT zhangjianghu longtermanalysisofmultimodalitytreatmentoutcomesandprognosisofesthesioneuroblastomasasinglecenterresultsof138patients
AT zhangshiping longtermanalysisofmultimodalitytreatmentoutcomesandprognosisofesthesioneuroblastomasasinglecenterresultsof138patients
AT chenxuesong longtermanalysisofmultimodalitytreatmentoutcomesandprognosisofesthesioneuroblastomasasinglecenterresultsof138patients
AT wangjingbo longtermanalysisofmultimodalitytreatmentoutcomesandprognosisofesthesioneuroblastomasasinglecenterresultsof138patients
AT wurunye longtermanalysisofmultimodalitytreatmentoutcomesandprognosisofesthesioneuroblastomasasinglecenterresultsof138patients
AT zhangye longtermanalysisofmultimodalitytreatmentoutcomesandprognosisofesthesioneuroblastomasasinglecenterresultsof138patients
AT yijunlin longtermanalysisofmultimodalitytreatmentoutcomesandprognosisofesthesioneuroblastomasasinglecenterresultsof138patients
AT xiaojianping longtermanalysisofmultimodalitytreatmentoutcomesandprognosisofesthesioneuroblastomasasinglecenterresultsof138patients
AT xuguozhen longtermanalysisofmultimodalitytreatmentoutcomesandprognosisofesthesioneuroblastomasasinglecenterresultsof138patients
AT huangxiaodong longtermanalysisofmultimodalitytreatmentoutcomesandprognosisofesthesioneuroblastomasasinglecenterresultsof138patients
AT luojingwei longtermanalysisofmultimodalitytreatmentoutcomesandprognosisofesthesioneuroblastomasasinglecenterresultsof138patients